Navigation Links
Publication of Shire plc's Annual Report 2008
Date:3/25/2009

the Company's filings with the Securities and Exchange Commission.

    APPENDIX
    1. Principal Risks and Uncertainties
    RISKS RELATED TO THE GROUP'S BUSINESS
    The Group's new products may not be a commercial success

Shire has launched a number of new products in the last four years, including key new products ELAPRASE, VYVANSE, LIALDA, FIRAZYR and FOSRENOL (Rest of World ('ROW')). The commercial success of these new products, as well as other new products that the Group may launch in the future, will depend on their approval and acceptance by physicians, patients and other key decision-makers, as well as the timing of the receipt of marketing approvals, the scope of marketing approvals as reflected in the product's label, the countries in which such approvals are obtained, the authorization of price and reimbursement in those countries where price and reimbursement is negotiated, and safety, efficacy, convenience and cost-effectiveness of the product as compared to competitive products.

The Group may not be able to grow revenues in its new products as quickly as anticipated if any or all of the following occur:

    - if competitive products are genericised and the impact on the market
      negatively affects the prescribing of branded treatments for the
      indications that the Group's new products treat;

    - if there are unanticipated adverse events experienced with the Group's
      new products not seen in clinical trials that impact the physician's
      willingness to prescribe the Group's new products;

    - if issues arise from clinical trials being conducted for post marketing
      purposes or for registration in another country or regulatory agencies
      in one country act in a way that causes concern for prescribers or
      patients in another country;

    - if patients, payors or physicians favor older treatments over newer
      treatments;

    -
'/>"/>
SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM)
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. InVitria Among Leading Innovators in Cell Culture Media According to Top Biotechnology Publication
4. BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
5. New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases
6. PharmSource and BioProcess Technology Consultants Announce Publication of New Market Report: Cell Culture Manufacturing Capacity: Trends and Outlook through 2013
7. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
8. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
9. Publication on Tregitopes in Blood Journal of October 2008
10. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
11. ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... , June 1, 2015 Esperance Pharmaceuticals ... trial of lead candidate EP-100 in ovarian cancer patients ... designed to seek and destroy cancer cells that overexpress ... receptors are over-expressed in a wide range of cancers. ... Phase II trial of EP-100 were presented at ...
(Date:6/1/2015)... BOSTON , June 1, 2015  Berg, a ... data-driven, biological approach, presented clinical research from its trials ... solid tumors and preclinical data on triple negative breast ... the American Society of Clinical Oncology (ASCO), May 29 ... BPM 31510 is one of the ...
(Date:6/1/2015)... June 1, 2015  Albany Molecular Research ... that it has signed a collaborative agreement ... their structure-based drug discovery services to global ... the three-year agreement, AMRI gains access to ... capabilities. HarkerBIO,s customers will be able to ...
(Date:6/1/2015)... 29, 2015 Research and Markets( ... the "2015 Strategies in the US ... their offering. This new 373-page ... comprehensive analysis of the POC clinical chemistry ... requirements, technological trends, competitive landscape, and emerging ...
Breaking Biology Technology:Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 2Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 3Berg Presents Data On BPM 31510 Solid Tumor Trial At ASCO Annual Meeting That Reveals The Promise Of Metabolically Driven Therapy 2Berg Presents Data On BPM 31510 Solid Tumor Trial At ASCO Annual Meeting That Reveals The Promise Of Metabolically Driven Therapy 3AMRI and HarkerBIO Ink Collaborative Agreement in Buffalo, N.Y. 2AMRI and HarkerBIO Ink Collaborative Agreement in Buffalo, N.Y. 3
... Wis. - Expect the face of small business to ... class diversifies to an even greater degree, according to a ... of small business sponsored by Intuit , the California-based ... authored by the Institute for the Future , paints ...
... Dr. William Yasnoff agreed that $30 million is ... the adoption of electronic health records, but not too small ... idea. , ,Yasnoff, founder of the eHealth Trust Initiative, continues ... or bank, for all electronic health records. He views a ...
... information officers try to measure their value in financial terms, and ... Sauk Sauk, vice president and CIO of University of ... on investment; he has in mind a more practical form of ... accepted in August of 2006, Sauk told UWHC executives that he ...
Cached Biology Technology:Small-business trends: Intuit sees more mom-preneurs 2Small-business trends: Intuit sees more mom-preneurs 3Small-business trends: Intuit sees more mom-preneurs 4Yasnoff: Wisconsin should invest in health record bank 2Yasnoff: Wisconsin should invest in health record bank 3CIO Leadership Series: Mike Sauk, UW Hospital and Clinics 2CIO Leadership Series: Mike Sauk, UW Hospital and Clinics 3CIO Leadership Series: Mike Sauk, UW Hospital and Clinics 4CIO Leadership Series: Mike Sauk, UW Hospital and Clinics 5
(Date:4/20/2015)... The announcement comes as demand ... Management (GRM), Ireland,s foremost records management ... built up an impressive track record of clients within the ... the records management sector in Dubai . ... staffbase and employ a further eight staff members at its ...
(Date:4/14/2015)... 2015  HYPR Corp. today announced it has ... Alliance tm , an industry consortium transforming online ... share technology and collaborate to deliver open specifications ... secure and private, and easier to use. ... protects sensitive user information and eliminates the dependency ...
(Date:4/13/2015)... , April 13, 2015 ... Research, "Global Biometrics Market Forecast & Opportunities, 2020", the ... CAGR of around 14% till 2020. The biometrics ... large scale implementation and review of biometric management ... of new products with greater efficiency, are resulting ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... For smokers with asthma, quitting smoking can improve lung function ... two months. , The findings appear in the second ... and Critical Care Medicine, published by the American Thoracic Society. ... Medicine and Immunology at the University of Glasgow, and seven ...
... more than 120,000 children under age 6 in Massachusetts ... young children--especially infants--are now more likely to be overweight. ... Care and Prevention of Harvard Medical School and Harvard ... of Obesity. , "The obesity epidemic has spared no ...
... to feed exclusively on blood, including human blood, recognize their ... published today in the open access journal BMC Biology, vampire ... breathing sounds much better than human participants could. Vampire bats ... authors of the study propose that the bats use breathing ...
Cached Biology News:Quitting smoking improves lung function considerably 2Today's babies are fatter babies 2
Rabbit polyclonal to hCG ( Abpromise for all tested applications). entrezGeneID: 1081 SwissProtID: P01215...
Glutathione Agarose Beads 10 ml...
...
Human Regulatory T cell Staining Kit #2 (w/ APC Foxp3 PCH101, FITC CD4, PE CD25)...
Biology Products: